Navigation Links
Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment
Date:9/10/2008

preferred shares equal to the $5,000,000 divided by the average closing market price for the common shares as of the date of the commitment or investment, whichever is higher (the "target price"). This series of stock will be redeemable (i.e., the investment will be repaid by Signalife) in five years, together with interest accrued at libor plus 2%. The investors may, after a one-year holding period, convert their investment in the series 'B' preferred shares, including accrued interest, into common shares at the ten-day average closing market price for the common shares as of the date of the conversion, but (1) not less the target price, and (2) not more than two-times the target price. Signalife will also have the right, after six months, to convert all of the series 'B' preferred shares, including accrued interest, into common shares at the ten-day average closing market price for the common shares, subject to the same floor and cap prices applicable to conversions by the holders of the series 'B' preferred shares. Each series 'B' preferred share shall be entitled to one vote on all corporate matters that may be submitted to the company's common shareholders, with the common and series 'B' preferred shares voting as a single class. The series 'B' preferred shares will have a liquidation preference over common shares and all other classes of preferred shares, with the exception of outstanding series 'A' preferred shares. The creation and sale of the series 'B' preferred shares may also be subject to applicable regulatory approvals. The company will also register the series 'B' preferred shares (to the extent permitted by the SEC) under a resale registration statement.

Signalife further announced that the board of directors has approved the creation of a new series of convertible preferred stock, to be designated series 'C', and the declaration of a dividend of those shares to all common shareholders and series 'B' preferred shareholders of record as of the
'/>"/>

SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Signalife Announces Anticipated Date of Transition to OTCBB
2. Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow
3. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
4. AFL To Return to Oklahoma Due to Overwhelming Demand for Signalife Heart Screening
5. Signalife Board Approves Merger
6. Signalife Announces AFL Joins NIH Education Program
7. Signalife Appoints Lee Ehrlichman President and Chief Operating Officer
8. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
9. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
10. Signalife Announces Webcast
11. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Delaware , August 3, 2015 ... in the commercialization of its Bio-electrical Signal Therapy device ... noninvasive treatment of hard to heal chronic wounds, today ... agreement with Chemipal, an Israeli distributor specializing in medical ... device. Chemipal is a 70 years old, ...
(Date:7/31/2015)... VEGAS , July 31, 2015 ... seek resources that help them drive positive health ... a vital source of patient care in their ... annual tradeshow and conference, AmerisourceBergen announced a ... its Pharmacy Services Administration Organization and help independent ...
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary ... of its canine osteoarthritis stem cell product, currently under development for FDA approval. ... will be marketed in the US by Aratana. This product, termed AT-016, is ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... May 3, 2012 PDL BioPharma, Inc. (PDL) (NASDAQ: ... quarter ended March 31, 2012. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) ... 2012 increased five percent over the same period of 2011. ... million, compared to $83.3 million for the same period of ...
... Having headquarters in one of the  world,s largest democracies ... sought after exporters of Hospital Furniture and Orthopedic Implants. Product ... are some of the unique selling propositions of the organization. ... for quite a few years now. We are very happy ...
... 3, 2012  Discovery Laboratories, Inc. (Nasdaq: DSCO ... new standard in respiratory critical care, today reports financial ... The Company will host a conference call this morning ... Key financial information includes: , For ...
Cached Biology Technology:PDL BioPharma Announces First Quarter 2012 Financial Results 2PDL BioPharma Announces First Quarter 2012 Financial Results 3PDL BioPharma Announces First Quarter 2012 Financial Results 4PDL BioPharma Announces First Quarter 2012 Financial Results 5Customer Satisfaction, A key to Success: Narang Medical Limited 2Discovery Labs Reports First Quarter 2012 Financial Results 2Discovery Labs Reports First Quarter 2012 Financial Results 3Discovery Labs Reports First Quarter 2012 Financial Results 4Discovery Labs Reports First Quarter 2012 Financial Results 5Discovery Labs Reports First Quarter 2012 Financial Results 6Discovery Labs Reports First Quarter 2012 Financial Results 7Discovery Labs Reports First Quarter 2012 Financial Results 8Discovery Labs Reports First Quarter 2012 Financial Results 9Discovery Labs Reports First Quarter 2012 Financial Results 10Discovery Labs Reports First Quarter 2012 Financial Results 11
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik (ICG-10, ... vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ihr ... ICG weltweit zu einem der einflussreichsten jährlichen Treffen ... dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/31/2015)... SHENZHEN, China , July 31, 2015 The ... ) will be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th ... become one of the world,s most influential annual meetings in ... enthusiastic, and enjoyable scientific gatherings. ICG-10 focuses ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... The University of Nottingham have taken some important first ... cell, a leading science journal reports. Dr Cameron ... School of Pharmacy have used polymers long-chain molecules ... the surfaces of a real cell. In work ...
... Des Moines, Iowa May 22, 2008 Dr. ... Trust of Iowa and a pioneer in the field ... eighth honorary doctor of science degree conferred in the ... at Springfield. Savage-Rumbaugh, an internationally known primatologist and ...
... unique ability to eat toxic mulberry leaves without feeling ... understanding why: silkworms contain a special digestive enzyme that ... leaves contain an extremely high amount of alkaloids that ... are potentially quite toxic. However, one type of sucrase ...
Cached Biology News:Life, but not as we know it? 2Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 2Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 3Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 4Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 5
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
Request Info...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: